Klingemann H G, Wong E
Terry Fox Laboratory, Division of Hematology, University of British Columbia, Vancouver, Canada.
Cancer Immunol Immunother. 1991;33(6):395-7. doi: 10.1007/BF01741600.
The activity of lymphokine-activated killer (LAK) cells is supported by various cytokines. The objective of this study was to see if recombinant interleukin-6 (IL-6) either alone or in combination with interleukin-2 (IL-2) has any effect on the generation of LAK cells. Peripheral blood mononuclear cells of healthy donors were cultured for 4 or 6 days with both cytokines either alone or in combination. LAK activity against K562 and natural killer-resistant Daudi cells was assessed by a 4-h and an 18-h 51Cr-release assay at various effector to target ratios. IL-6 alone in increasing concentrations did not induce LAK cell activity. Neither additive nor synergistic effects of IL-6 with IL-2 were observed. Immunofluorescence analysis with phycoerythrin-conjugated anti-CD56 antibody demonstrated that IL-6 could not maintain or increase the number of CD56-positive cells over a 6-day culture period. These results suggest that IL-6 does not support LAK cell generation by itself or increase LAK cell activity in combination with IL-2.
多种细胞因子可支持淋巴因子激活的杀伤(LAK)细胞的活性。本研究的目的是观察重组白细胞介素-6(IL-6)单独或与白细胞介素-2(IL-2)联合使用时,对LAK细胞生成是否有任何影响。将健康供体的外周血单个核细胞分别用两种细胞因子单独或联合培养4天或6天。在不同的效应细胞与靶细胞比例下,通过4小时和18小时的51Cr释放试验评估针对K562和自然杀伤抗性Daudi细胞的LAK活性。单独增加浓度的IL-6未诱导LAK细胞活性。未观察到IL-6与IL-2的相加或协同作用。用藻红蛋白偶联的抗CD56抗体进行的免疫荧光分析表明,在6天的培养期内,IL-6不能维持或增加CD56阳性细胞的数量。这些结果表明,IL-6本身不支持LAK细胞的生成,也不能与IL-2联合增加LAK细胞活性。